Andi Yasmin WIJAYA, Winona May HENDRATA, Muhammad Noor DIANSYAH, Ami Ashariati PRAYOGO, Made Putra SEDANA, Merlyna SAVITRI, Pradana Zaky ROMADHON, Putu Niken Ayu AMRITA, Ugroseno Yudho BINTORO

Early detection breast cancer: role of circulating plasma miRNA-21 expression as a potential screening biomarker

Background/aim: To explore the potential of the circulating plasma miRNA-21 as an early detection biomarker by comparing earlystage breast cancer (BG) and healthy control (HG) in Indonesian population. Materials and methods: The enlisted patients were 26 adult female early-stage breast cancer patients (stage 1A, 1B, 2A, and 2B) of Airlangga University Hospital from August 2019 to October 2019. Sixteen volunteers were recruited as matching healthy subjects. MiRNA-21 expression was quantified by plasma qRT-PCR. Data analysis performed using IBM SPSS Statistics v.24 (IBM Corp., Armonk, NY, USA). MiRNA-21 cut-off, sensitivity, and specificity were analyzed using receiver operating characteristic (ROC) curve. Results: The study included 26 BG and 16 HG subjects. The miRNA-21 expression in BG group was 3.933 (1.181-11.794) and 0.905 (0.164-4.532) in HG group (4.34 folds; P = 0.001), with 1.66 cut-off (92.3% sensitivity; 81.2% specificity). MiRNA-21 expression separated analysis in HG showed a 0.578 times lower expression in menopause subjects [0.651 (0.164-0.414)], compared to premenopause ones [(1.123 (0.758 - 4.532); P = 0.031]. Yet, in BG group, 1.729 times higher miRNA-21 expression was observed in menopause subjects (6.021 ± 3.583), compared to premenopause ones (3.500 ± 1.517; P = 0.022). Conclusion: Circulating miRNA-21 expression is a potential biomarker for early detection of breast cancer and might act as a breast cancer risk predictor.Key words: Biomarkers, breast neoplasms, diagnosis, human plasma, miRNA-21

PDF

___

1. Zhu W, Harvey S, Macura KJ, Euhus DM, Artemov D. Invasive breast cancer preferably and predominantly occurs at the interface between fibroglandular and adipose tissue. Clinical Breast Cancer 2017; 17 (1): e11-e18. doi: 10.1016/j. clbc.2016.07.009
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 2018; 68 (6): 394-424. doi: 10.3322/caac.21492
3. Kharkwal S, Sameer A, Mukherjee A. Triple test in carcinoma breast. Journal of Clinical and Diagnostic Research 2014; 8 (10): NC09–NC11. doi: 10.7860/JCDR/2014/9237.4971
4. Perakis S, Speicher MR. Emerging concepts in liquid biopsies. BioMed Central Medicine 2017; 15 (1): 75. doi: 10.1186/ s12916-017-0840-6
5. Heywang-Köbrunner SH, Hacker A, Sedlacek S. Advantages and disadvantages of mammography screening. Breast Care 2011; 6 (3): 199-207. doi: 10.1159/000329005
6. Guo R, Lu G, Qin B, Fei B. Ultrasound imaging technologies for breast cancer detection and management: a review. Ultrasound in Medicine and Biology 2018; 44 (1): 37-70. doi: 10.1016/j. ultrasmedbio.2017.09.012
7. Ng EKO, Li R, Shin VY, Jin HC, Leung CPH et al. Circulating microRNAs as specific biomarkers for breast cancer detection. Public Library of Science One 2013; 8 (1): e53141. doi: 10.1371/ journal.pone.0053141
8. Gao J, Zhang Q, Xu J, Guo L, Li X. Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA. Chinese Journal of Cancer Research 2013; 25 (6): 743- 748. doi: 10.3978/j.issn.1000-9604.2013.12.04
9. Uehara M, Kinoshita T, Hojo T, Akashi-Tanaka S, Iwamoto E et al. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. International Journal of Clinical Oncology 2008; 13 (5): 447-451. doi: 10.1007/s10147-008-0773-3
10. Pan X, Wang Z-X, Wang R. MicroRNA-21: A novel therapeutic target in human cancer. Cancer Biology and Therapy 2010; 10 (12): 1224-1232. doi: 10.4161/cbt.10.12.14252
11. Iorio M V, Croce CM. Causes and consequences of microRNA dysregulation. The Cancer Journal 2012; 18 (3): 215-222. doi: 10.1097/PPO.0b013e318250c001
12. Rani GSBS, Bitla AR. Breast cancer diagnosis – role of biomarkers. Journal of Clinical and Scientific Research 2017; 6 (4): 225-236. doi: 10.15380/2277-5706.JCSR.17.08.005
13. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Kerin MJ. MicroRNAs as novel biomarkers for breast cancer. Journal of Oncology 2009; Special Issue: 950201. doi: 10.1155/2010/950201
14. Hug KA, Anthony L, Eldeiry D, Benson J, Wheeler E et al. Expression and tissue distribution of MicroRNA-21 in malignant and benign breast tissues. Anticancer Research 2015; 35 (6): 3175-3183
15. Zhu S, Wu H, Wu F, Nie D, Sheng S et al. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Research 2008; 18: 350-359. doi: 10.1038/cr.2008.24
16. Fu SW, Chen L, Man Y-G. miRNA biomarkers in breast cancer detection and management. Journal of Cancer 2011; 2: 116- 122. doi: 10.7150/jca.2.116
17. Cui M, Wang H, Yao X, Zhang D, Xie Y et al. Circulating MicroRNAs in cancer: potential and challenge. Frontiers in Genetics 2019; 10: 626. doi: 10.3389/fgene.2019.00626
18. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB et al. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. Public Library of Science One 2010; 5 (10): e13735. doi:10.1371/journal.pone.0013735
19. Mar-Aguilar F, Mendoza-Ramírez JA, Malagón-Santiago I, Espino-Silva PK, Santuario-Facio SK et al. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Disease Markers 2013; 34 (3): 163-169. doi: 10.3233/DMA-120957
20. Usmani A, Shoro AA, Memon Z, Hussain M, Rehman R. Diagnostic, prognostic and predictive value of MicroRNA-21 in breast cancer patients, their daughters and healthy individuals. American Journal of Cancer Research 2015; 5 (8): 2484-2490
21. Tiberio P, Callari M, Angeloni V, Daidone MG, Appierto V. Challenges in using circulating miRNAs as cancer biomarkers. BioMed Research International 2015; Special Issue: 731479. doi: 10.1155/2015/731479
22. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK et al. Circulating microRNAs as stable blood-based markers for cancer detection. In: Proceedings of the National Academy of Sciences of the United States of America 2008; Seattle, WA, USA. 105 (30): pp. 10513-10518. doi: 10.1073/pnas.0804549105
23. Fattah HIA, Mahmoud NH, Elzoghby DM, Matar MM, ElShaer IMM. Clinical utility of circulating MicroRNA-21 in breast cancer. The Egyptian Journal of Hospital Medicine 2018; 71 (4): 2950-2955.
24. Wang B, Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of 5 solid tumors. Journal of Cancer Research and Clinical Oncology 2012; 138 (10): 1659-1666. doi: 10.1007/s00432-012-1244-9
25. Elghoroury EA, ElDine HG, Kamel SA, Abdelrahman AH, Mohammed A et al. Evaluation of miRNA-21 and miRNA Let-7 as prognostic markers in patients with breast cancer. Clinical Breast Cancer 2018; 18 (4): e721-e726. doi: 10.1016/j. clbc.2017.11.022
26. Kahraman M, Röske A, Laufer T, Fehlmann T, Backes C et al. MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer. Scientific Reports 2018; 8: 11584. doi: 10.1038/s41598-018-29917-2
27. Cui J, Shen Y, Li R. Estrogen synthesis and signaling pathways during aging: from periphery to brain. Trends in Molecular Medicine 2013; 19 (3): 197-209. doi: 10.1016/j. molmed.2012.12.007
28. Qureshi R, Picon-Ruiz M, Aurrekoetxea-Rodriguez I, Paiva VN, D’Amico M et al. The major pre- and postmenopausal estrogens play opposing roles in obesity-driven mammary inflammation and breast cancer development. Cell Metabolism 2020;. 31 (6): 1154-1172.e9. doi: 10.1016/j.cmet.2020.05.008
29. Ma X, Buscaglia LEB, Barker JR, Li Y. MicroRNAs in NF-κB signaling. Journal of Molecular Cell Biology 2011; 3 (3): 159- 166. doi: 10.1093/jmcb/mjr007
30. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, Martin C, O’Leary JJ et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nature Immunology 2010; 11 (2): 141-147. doi: 10.1038/ni.1828